Home/Pipeline/SBX 2048

SBX 2048

HIV

Early-stage ClinicalActive

Key Facts

Indication

HIV

Phase

Early-stage Clinical

Status

Active

Company

Stramsen Biotech

About Stramsen Biotech

Stramsen Biotech is an early-stage, private biotech firm pioneering a plant-based drug discovery and development platform. It boasts a robust pipeline of 33 drug candidates, with 11 in early-stage clinical trials, targeting major therapeutic areas including oncology, cardiovascular disease, HIV, and diabetes. The company claims a $19 billion valuation from a third-party appraisal and is backed by lead investor GEM Global Yield LLC SCS, positioning it for significant growth as it advances candidates toward FDA submissions.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Diseases Infectious Disease (HIV)Metabolic Disorders (Diabetes)Neurological Disorders Musculoskeletal Disorders (Arthritis)Urology Wound Care Nephrology

Other HIV Drugs

Drug	Company	Phase	Status
Vaxine HIV Vaccine	Vaxine	Preclinical	Active
OraQuick® HIV Self-Test	OraSure	Commercial	FDA Approved; Marketed
Tenofovir Disoproxil Fumarate	Hetero	Commercial	Active
NanoDDI	Continuity Biosciences	Pre-clinical	Active
HIV Gene Therapy	Nanite	Pre-clinical	Active
RGFields for HIV	Anapole Technologies	Clinical (phase unspecified)	Active
HIV mAb Program	Adnexus	Pre-clinical	Active
Undisclosed Program	EnnoDC	Phase 1	Active
O2-16 Series	OyaGen	Preclinical	Active
ALF Platform	Senzo	Pre-clinical	Active
Gilead HIV Franchise	Royalty Pharma	Marketed	Active
ANKTIVA-based regimens	ImmunityBio	Phase 1/2	Active